Adverse Events following Administration to Pregnant Women of Influenza A (H1N1) 2009 Monovalent Vaccine reported to the Vaccine Adverse Event Reporting System (VAERS).

MORO, Pedro L.; BRODER, Karen; ZHETEYEVA, Yenlik; REVZINA, Natalya; TEPPER, Naomi; KISSIN, Dmitry; BARASH, Faith; ARANA, Jorge; BRANTLEY, Mary D.; DING, Helen; SINGLETON, James A.; WALTON, Kimp; HABER, Penina; LEWIS, Paige; YUE, Xin; DESTEFANO, Frank; VELLOZZI, Claudia

doi:10.1016/j.ajog.2011.06.047

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Adverse Events following Administration to Pregnant Women of Influenza A (H1N1) 2009 Monovalent Vaccine reported to the Vaccine Adverse Event Reporting System (VAERS).

Published Date:

June 21 2011

Publisher's site:

http://dx.doi.org/10.1016/j.ajog.2011.06.047 New Site Icon

Source:

Am J Obstet Gynecol. 205(5):473.e1-473.e9

Language:

English

[PDF-188.28 KB]

Details:

Personal Authors:

MORO, Pedro L. ; BRODER, Karen ; ZHETEYEVA, Yenlik ; REVZINA, Natalya ; TEPPER, Naomi ; ... More ▼

Keywords:

[+]

Pubmed ID:

21861964

Pubmed Central ID:

PMC6602056

Description:

Objective:

To evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system, in pregnant women who received Influenza A (H1N1) 2009 Monovalent Vaccine to assess for potential vaccine safety problems.

Methods:

We reviewed reports of adverse events (AEs) in pregnant women who received 2009-H1N1 vaccines from 10/0½009–02/28/2010.

Results:

VAERS received 294 reports of AEs in pregnant women who received 2009-H1N1 vaccine: 288 after inactivated and 6 after the live attenuated vaccines. Two maternal deaths were reported. Fifty-nine (20.1%) women were hospitalized. We verified 131 pregnancy-specific outcomes: 95 spontaneous abortions (<20 weeks), 18 stillbirths (≥20 weeks), 7 preterm deliveries (<37 weeks), 3 threatened abortions, 2 preterm labor, 2 preeclampsia, and 1 each of fetal hydronephrosis, fetal tachycardia, intrauterine growth retardation, and cleft lip.

Conclusions:

Review of reports to VAERS following H1N1 vaccination in pregnant women did not identify any concerning patterns of maternal or fetal outcomes.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

CC999999/Intramural CDC HHS/United States

Main Document Checksum:

[+]

Supporting Files:

	nihms-1025602-f0001.gif	image/gif
	nihms-1025602-f0001.jpg	image/jpeg
	nihms-1025602.nxml	text/xml

No Related Documents.

You May Also Like:

Surveillance of adverse events after seasonal influenza vaccination in pregnant women and their infants in the Vaccine Adverse Event Reporting System, July, 2010 – May, 2016

Personal Author:

Moro, Pedro; Baumblatt, Jane; Lewis, Paige; Cragan, Janet; Tepper, Naomi; Cano, Maria;

Published:

February 2017

Source:

Drug Saf. 40(2):145-152

Description:

Introduction: : Routine immunization of pregnant women with seasonal inactivated influenza vaccines (IIV) is recommended in all trimesters of pregnancy. A review of the Vaccine Adverse Event Reporting System (VAERS) during 1990–2009 did not find an...

File Type:

[PDF - 387.00 KB]
Chorioamnionitis Following Vaccination in the Vaccine Adverse Event Reporting System

Personal Author:

Datwani, Hema; Moro, Pedro L.; Harrington, Theresa; Broder, Karen;

Published:

May 11 2015

Source:

Vaccine. 33(27):3110-3113

Description:

Background: : In October 2012, the Advisory Committee on Immunization Practices (ACIP) recommended a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) during each pregnancy, irrespective of the patient’s prior histor...

File Type:

[PDF - 301.62 KB]
Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention

Personal Author:

Moro, Pedro L.; Li, Rongxia; Haber, Penina; Weintraub, Eric; Cano, Maria;

Published:

June 16 2016

Source:

Expert Opin Drug Saf. 15(9):1175-1183

Description:

Introduction: : Annual influenza vaccine safety monitoring is an important component of the influenza vaccination program in the United States to ensure that vaccines are safe, which is important for maintaining public trust in the national vaccinati...

File Type:

[PDF - 645.84 KB]
Safety of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Pregnancy: Review of Non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006 – 2013

Personal Author:

Moro, Pedro L.; Zheteyeva, Yenlik; Lewis, Paige; Shi, Jing; Yue, Xin; Museru, Oidda I.; Broder, Karen;

Published:

December 08 2014

Source:

Vaccine. 33(4):519-522

Description:

Background: : In 2006, quadrivalent human papillomavirus (HPV4; Gardasil, Merck & Co. Inc.) vaccine was licensed in the US for use in females aged 9 to 26 years. HPV4 is not recommended during pregnancy; however, inadvertent administration during pre...

File Type:

[PDF - 58.54 KB]
Reports to the Vaccine Adverse Event Reporting System (VAERS) after Hepatitis A and Hepatitis AB Vaccines in Pregnant women

Personal Author:

MORO, Pedro L.; MUSERU, Oidda I.; NIU, Manette; LEWIS, Paige; BRODER, Karen;

Published:

December 27 2013

Source:

Am J Obstet Gynecol. 210(6):561.e1-561.e6

Description:

Objective: : To characterize adverse events (AEs) after Hepatitis A vaccines (Hep A) and Hepatitis A and Hepatitis B combination vaccine (Hep AB) in pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reportin...

File Type:

[PDF - 74.45 KB]